Effect of radiographic contrast media on markers of complement activation and apoptosis in patients with chronic coronary artery disease undergoing coronary angiography.
The effects of radiographic contrast media on markers of complement activation and apoptosis in patients with chronic coronary artery disease (CAD) are unknown. The purpose of this study was to assess the comparative effects of ionic high-osmolar and non-ionic iso-osmolar radiographic contrast media on plasma markers of complement activation and apoptosis in patients with chronic CAD undergoing coronary angiography. Forty-four patients undergoing coronary angiography for chronic CAD were randomly assigned to receive the ionic high-osmolar radiographic contrast agent diatrizoate (Group A), or the non-ionic iso-osmolar contrast agent iodixanol (Group B) during angiography. Complement component 5 (C5a) and apoptotic markers sFas and sFasL were measured just prior to angiography and 1 hour after completion of angiography. Comparison of mean pre- and post-angiography plasma marker levels showed significantly greater increases in plasma levels in Group A than in Group B of C5a (29.30 +/- 5.45 ng/ml for Group A and 0.47 +/- 0.70 ng/ml for Group B (p < 0.00001), sFas (2.36 +/- 1.63 ng/ml for Group A and 0.23 +/- 0.90 ng/ml for Group B (p < 0.00001) and sFasL (14.00 +/- 5.41 pg/ml for Group A and 0.01 +/- 1.00 pg/ml for Group B (p < 0.00001). The results suggest that in patients with chronic CAD, the use of ionic high-osmolar radiographic contrast media during coronary angiography is associated with a more robust inflammatory and apoptotic milieu than that associated with the use of non-ionic iso-osmolar radiographic contrast media.
Deftereos
Spyridon
S
Department of Cardiology, Athens General Hospital, Athens, Greece.
Giannopoulos
Georgios
G
Kossyvakis
Charalampos
C
Raisakis
Konstantinos
K
Kaoukis
Andreas
A
Driva
Metaxia
M
Ntzouvara
Olga
O
Panagopoulou
Vasiliki
V
Rentoukas
Ilias
I
Nikas
Dimitrios J
DJ
Pyrgakis
Vlasios
V
Alpert
Martin A
MA
D000368:Aged; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D015415:Biomarkers / Q000097:blood; D003167:Complement Activation / Q000187:drug effects* / Q000502:physiology; D015936:Complement C5a / Q000378:metabolism; D003287:Contrast Media / Q000494:pharmacology; D017023:Coronary Angiography / Q000379:methods*; D003324:Coronary Artery Disease / Q000097:blood* / Q000000981:diagnostic imaging*; D003973:Diatrizoate / Q000494:pharmacology*; D053222:Fas Ligand Protein / Q000097:blood; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009994:Osmolar Concentration; D014283:Triiodobenzoic Acids / Q000494:pharmacology*; D019014:fas Receptor / Q000097:blood
D015415:Biomarkers; D003287:Contrast Media; D053222:Fas Ligand Protein; D014283:Triiodobenzoic Acids; D019014:fas Receptor; D003973:Diatrizoate; D015936:Complement C5a; C044834:iodixanol